Acridine carboxamide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Acridine carboxamide
Acridine carboxamide.svg
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C8H19N3O
Molar mass 293.363 g/mol
3D model (JSmol)

Acridine carboxamide is an chemotherapy agent that is being studied in the treatment of cancer. It belongs to the family of drugs called topoisomerase inhibitors.

While the agent was well tolerated in Phase II clinical trials, it did not show efficacy when tested against various types of cancers.[1][2][3][4]

See also[edit]

References[edit]

  1. ^ Dittrich C, Dieras V, Kerbrat P, et al. (2003). "Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer". Investigational new drugs. 21 (3): 347–52. PMID 14578683. doi:10.1023/A:1025476813365. 
  2. ^ Caponigro F, Dittrich C, Sorensen JB, et al. (2002). "Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer". Eur. J. Cancer. 38 (1): 70–4. PMID 11750842. doi:10.1016/S0959-8049(01)00336-7. 
  3. ^ Twelves C, Campone M, Coudert B, et al. (2002). "Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme". Ann. Oncol. 13 (5): 777–80. PMID 12075748. doi:10.1093/annonc/mdf121. 
  4. ^ Dittrich C, Coudert B, Paz-Ares L, et al. (2003). "Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer". Eur. J. Cancer. 39 (3): 330–4. PMID 12565985. doi:10.1016/S0959-8049(02)00559-2.